Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS EBITDA Margin

EBITDA as a percentage of revenue.

Kalaris Therapeutics IncNASDAQ: KLRS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How KLRS compares with its peers on the latest reported figures

KLRS Competitors Peer median
EBITDA Margin for KLRS and competitors
Company Period LTM level YoY 3-year change
STROSutro Biopharma, Inc.LTM Mar 2026-106.5% +169.1 pp+12.9 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-337.0% +4411.9 pp+3368.5 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4623.1% -3172.4 pp+10652.3 pp
IMAImageneBio IncFY2025-5583.3% -4582.4 pp-5147.8 pp
CNTBConnect Biopharma Holdings LimitedFY2025-85279.7% -85223.0 pp—
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
KLRSKalaris Therapeutics IncFY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding KLRS) -5103.2%-3877.4 pp+1690.7 pp

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.